The paradox at the heart of Rocket Lab’s current market position is almost mechanical in its cruelty. The company’s planned $8 billion acquisition of Iridium Communications is structured with a variable exchange ratio tied to Rocket Lab’s own share price near the deal’s closing date. Every dollar the stock loses doesn’t just dent investor portfolios — it makes the acquisition more expensive in real terms. And the regulatory friction that could derail the deal is itself one of the forces pushing the shares down.
That feedback loop helps explain why a company delivering record revenue and launching rockets at an unprecedented cadence finds its equity stuck in a persistent slide. The shares closed at €55.10 on Monday, roughly 18.5 percent below where they traded before the Archimedes engine announcement more than a month ago.
The Numbers Tell One Story
The operational picture remains genuinely strong. Rocket Lab posted record second-quarter revenue of $234 million, up 62 percent year over year, with a backlog of $2.36 billion. Management guided to combined full-year revenue of $1.8 billion, a figure that already incorporates the Iridium acquisition. For the third quarter, the company expects revenue between $250 million and $265 million.
The launch schedule underscores the momentum. The Electron rocket completed its 92nd, 93rd, and 94th missions in August alone, including satellite deliveries for iQPS and Synspective. The company has now logged 15 launches this year and is approaching the symbolic 100th Electron flight. Today’s mission — carrying a StriX-series radar satellite for Japanese operator Synspective from New Zealand — continues that rhythm.
Government business is expanding too. The US Space Force selected Rocket Lab for a consortium building a global data network valued at $12 million, and the company was brought into the multibillion-dollar NITE-STAR program for test infrastructure development. Early August brought a $397 million contract to build flatellites for a military target-acquisition program.
The Chart Tells Another
None of that operational strength is visible in the price action. The stock has shed 12 percent over the past 30 days and sits 12 percent lower year to date. At €54.10, it trades roughly 60 percent below its May peak of €133.80 and remains well under the 200-day moving average of €69.52 — a technical picture that suggests the downtrend has yet to find a floor. The relative strength index sits at 32.9, flirting with oversold territory, though technicians would caution that oversold conditions can persist.
The insider selling that surfaced in late August added to the unease. Five executives, including COO Frank Klein and CFO Adam Spice, disposed of nearly 78,800 shares worth a combined $5.49 million. Klein’s tranche alone came to roughly $2.37 million, sold at prices between $66.25 and $67.54 per share.
Should investors sell immediately? Or is it worth buying Rocket Lab?
The filings tell a more benign story than the headline numbers suggest. These were sell-to-cover transactions — automatic dispositions to satisfy tax obligations on vesting equity awards, not discretionary bets against the company. The executives retained roughly 97.5 percent of their holdings. Still, in a nervous market, even mechanical selling registers as a signal.
The Regulatory Squeeze
SpaceX’s late-August filing with the FCC, urging closer scrutiny of Iridium’s conduct during the license transfer review, knocked roughly 6 percent off the share price. The objection adds another layer of uncertainty to a deal already facing a crowded timeline. Iridium shareholders vote on September 24, a date now viewed as the next critical checkpoint.
The financing structure adds its own pressure. Rocket Lab has established an equity program worth $1.94 billion to fund the cash portion of the deal and retire a $3.6 billion bridge facility. Any significant drawdown would dilute existing shareholders — a prospect that hangs over the stock even before the regulatory questions are resolved.
Timing Slips and Expansion Moves
The Neutron program has also given investors reason to temper expectations. Early August signals suggested a 2026 launch is far from certain, with Bloomberg reporting a possible slip into 2027. The Kodiak site for the GHOST system has similarly moved to 2027 from its original late-2026 target.
Yet the company continues to expand its footprint. A Neutron launch contract with Kepler Communications and the establishment of a German subsidiary position Rocket Lab for European sovereign space requirements — a market with growing strategic importance.
The central question for investors has shifted from whether Rocket Lab can execute operationally — it clearly can — to whether the Iridium deal can clear its regulatory hurdles without the company’s own capital structure or share price becoming an obstacle to the transaction’s completion. The two-speed reality of record fundamentals and a deteriorating chart may ultimately converge, but the direction of that convergence remains very much in play.
Ad
Rocket Lab Stock: Buy or Sell?! New Rocket Lab Analysis from September 1 delivers the answer:
The latest Rocket Lab figures speak for themselves: Urgent action needed for Rocket Lab investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 1.
Rocket Lab: Buy or sell? Read more here...
